Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Molecular Screening Applying a Pan-Myeloid Gene Panel Reveals Mutations in All Patients with Acute Undifferentiated Leukemia

Wolfgang Kern, MD, Sabrina Kuznia, M.Sc., Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach

Blood (2014) 124 (21): 2392.

https://doi.org/10.1182/blood.V124.21.2392.2392

Published: 2014

Journal Articles

TP53 mutations occur in 15.7% of ALL and are associated with MYC -rearrangement, low hypodiploidy, and a poor prognosis

Anna Stengel, Susanne Schnittger, Sandra Weissmann, Sabrina Kuznia, Wolfgang Kern, Alexander Kohlmann, Torsten Haferlach, Claudia Haferlach

Blood (2014) 124 (2): 251–258.

https://doi.org/10.1182/blood-2014-02-558833

Published: 2014

Includes: Supplemental data

Journal Articles

WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis

Susanne Schnittger, PhD, Christiane Eder, PhD, Tamara Alpermann, Frank Dicker, PhD, Madlen Ulke, Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 2542.

https://doi.org/10.1182/blood.V122.21.2542.2542

Published: 2013

Journal Articles

Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability

Susanne Schnittger, PhD, Niroshan Nadarajah, MSc, Tamara Alpermann, Christiane Eder, PhD, Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Sandra Weissmann, PhD, Annette Fasan, PhD, Simone Weber, Andreia Albuquerque, PhD, Sabine Jeromin, PhD, Manja Meggendorfer, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2013) 122 (21): 4978.

https://doi.org/10.1182/blood.V122.21.4978.4978

Published: 2013

Journal Articles

Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies

Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Niroshan Nadarajah, MSc, Tamara Alpermann, Sandra Weissmann, PhD, Andreas Roller, PhD, Andreia Albuquerque, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 1547.

https://doi.org/10.1182/blood.V122.21.1547.1547

Published: 2013

Journal Articles

Molecular Screening In Blastic Plasmacytoid Dendritic Cell Neoplasms Reveals Mutations In TET2 and ASXL1 In The Majority Of Patients

Wolfgang Kern, MD, Sabrina Kuznia, MSc, Susanne Schnittger, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD, Alexander Kohlmann, PhD

Blood (2013) 122 (21): 2581.

https://doi.org/10.1182/blood.V122.21.2581.2581

Published: 2013

Journal Articles

Targeted Next-Generation Sequencing Of 2,761 Genes Detects Copy Number States and Molecular Mutations In a Single Approach

Alexander Kohlmann, PhD, Andreas Roller, PhD, Sandra Weissmann, PhD, Sabrina Kuznia, MSc, Melanie Zenger, Wolfgang Kern, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 1371.

https://doi.org/10.1182/blood.V122.21.1371.1371

Published: 2013

Journal Articles

Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes

Susanne Schnittger, PhD, Sabrina Kuznia, MSc, Manja Meggendorfer, PhD, Niroshan Nadarajah, MSc, Sabine Jeromin, PhD, Tamara Alpermann, Andreas Roller, PhD, Andreia Albuquerque, PhD, Sandra Weissmann, PhD, Thomas Ernst, Christiane Eder, PhD, Frank Dicker, PhD, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Andreas Hochhaus, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 611.

https://doi.org/10.1182/blood.V122.21.611.611

Published: 2013

Journal Articles

TP53 Mutations Are Present In 15.7% Of ALL, Are Especially Frequent In ALL With MYC -Rearrangement and In ALL With Low Hypodiploid Chromosome Status and Are Associated With Poor Prognosis

Claudia Haferlach, MD, Sandra Weissmann, PhD, Sabrina Kuznia, MSc, Susanne Schnittger, PhD, Wolfgang Kern, MD, Alexander Kohlmann, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 827.

https://doi.org/10.1182/blood.V122.21.827.827

Published: 2013

Journal Articles

A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics

Alexander Kohlmann, PhD, Andreas Roller, PhD, Andreia Albuquerque, PhD, Sabrina Kuznia, MSc, Sandra Weissmann, PhD, Sabine Jeromin, PhD, Wolfgang Kern, MD, Claudia Haferlach, MD, Susanne Schnittger, PhD, Torsten Haferlach, MD

Blood (2013) 122 (21): 867.

https://doi.org/10.1182/blood.V122.21.867.867

Published: 2013

NARROW

Molecular Screening Applying a Pan-Myeloid Gene Panel Reveals Mutations in All Patients with Acute Undifferentiated Leukemia

TP53 mutations occur in 15.7% of ALL and are associated with MYC -rearrangement, low hypodiploidy, and a poor prognosis

WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis

Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability

Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies

Molecular Screening In Blastic Plasmacytoid Dendritic Cell Neoplasms Reveals Mutations In TET2 and ASXL1 In The Majority Of Patients

Targeted Next-Generation Sequencing Of 2,761 Genes Detects Copy Number States and Molecular Mutations In a Single Approach

Tyrosine Kinase Inhibitor Treated CML Patients Harboring Philadelphia-Negative Cytogenetically Aberrant Clones Show Molecular Mutations In 31% Of Cases Not Present At Diagnosis: A High-Throughput Amplicon Sequencing Study Of 29 Genes

TP53 Mutations Are Present In 15.7% Of ALL, Are Especially Frequent In ALL With MYC -Rearrangement and In ALL With Low Hypodiploid Chromosome Status and Are Associated With Poor Prognosis

A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only